Vladimir Skljarevski

Dr. Vladimir (Vlad) Skljarevski brings to Tetra more than 20 years of leadership and global neuroscience drug development experience across all phases of clinical research in academia, big pharma, and small biotech companies. As a global medical leader at Eli Lilly and Company, he designed and conducted over 20 large Phase 2 and Phase 3 trials which represented the basis for the worldwide registration of two products – Cymbalta for chronic pain, and Emgality for migraine prevention. He has an extensive regulatory, clinical operations, business development, and partnership building experience within the US, the EU, Japan, and China. More recently, he was the Executive Medical Director at Cortexyme and the Vice President of Clinical Development at Axial Therapeutics with direct responsibilities for their late-phase clinical programs in Alzheimer’s Disease and Autism Spectrum Disorder, respectively.

Dr. Skljarevski holds an MD degree from the University of Sarajevo in his native Bosnia and Herzegovina. He is a fully trained neurosurgeon with stereotactic fellowship training from Karolinska Hospital in Stockholm, Sweden. He also completed a neurology residency at the University of Vermont in Burlington, VT, as well as a clinical fellowship in cerebrovascular diseases at the University of Ottawa in Canada. Vlad holds an active medical license in the State of Indiana.